A new targeted therapy ("CB-839" a "glutaminase inhibitor") clinical trial specifically for CRC patients with PI3KC mutations (e.g. a part of the Foundation report and major cancer center/genomics venders mutation lists). It targets a metabolism enzyme that CRC tumors of that genetic background may be especially sensitive to inhibition, based on preclinical models.
It is combined with Xeloda in the the trial. They saw synergy with 5-FU in preclinical models. You can enter the trial after you have progressed on ANY 5-FU containing treatment plan - so very flexible.
At the Cleveland Clinic
https://clinicaltrials.gov/ct2/show/NCT ... 300&rank=1
The scientific poster of the Cleveland Clinic's preclinical CRC research:
http://www.calithera.com/wp-content/upl ... g-2015.pdf